Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2010-7-14
pubmed:abstractText
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable clinical course. The aim of this study was to evaluate whether a combination of genetic parameters can improve prediction of outcome irrespective of clinical stage. The prognostic impact of chromosome banding analysis (CBA) in addition to FISH and IgVH mutation status was evaluated. In total, 482 patients were analyzed, but evaluation of prognostic factors was restricted to 399 untreated cases. The prognostic significance of age, white blood cell (WBC) count, IgVH status, and TP53 and ATM deletions was confirmed. In addition, a prognostic impact of translocations involving the IGH@ locus (t(IgH)) and of a complex aberrant karyotype was found. On the basis of these results, we propose a scoring system for overall survival (OS) based on: age >or=65 years, WBC >or=20 x 10(9)/l, unmutated IgVH status, TP53 deletion, t(IgH), and the number of chromosome aberrations observed with CBA. Three risk groups showed considerable differences in OS (94.5% vs. 64.3% vs. 41.1% surviving at 5 years, P < 0.0001). Time to treatment (TTT) can be predicted best by unmutated IgVH status, ATM deletion, t(IgH), and number of chromosome aberrations. Four distinct subgroups were separated with median TTT of 110.7 months, 39.8 months, 19.5 months, and 3.8 months, respectively (P < 0.0001). In conclusion, cytogenetic data from CBA add prognostic information. The proposed scoring systems for OS and TTT based on a combination of genetic markers improve the separation of prognostic subgroups in CLL already early in the course of the disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1098-2264
pubmed:author
pubmed:copyrightInfo
(c) 2010 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
851-9
pubmed:dateRevised
2011-11-2
pubmed:meshHeading
pubmed-meshheading:20552631-Adult, pubmed-meshheading:20552631-Aged, pubmed-meshheading:20552631-Aged, 80 and over, pubmed-meshheading:20552631-Cell Cycle Proteins, pubmed-meshheading:20552631-Chromosome Aberrations, pubmed-meshheading:20552631-Chromosome Banding, pubmed-meshheading:20552631-DNA-Binding Proteins, pubmed-meshheading:20552631-Female, pubmed-meshheading:20552631-Gene Deletion, pubmed-meshheading:20552631-Humans, pubmed-meshheading:20552631-Immunoglobulin Heavy Chains, pubmed-meshheading:20552631-Immunoglobulin Variable Region, pubmed-meshheading:20552631-In Situ Hybridization, Fluorescence, pubmed-meshheading:20552631-Karyotyping, pubmed-meshheading:20552631-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:20552631-Male, pubmed-meshheading:20552631-Middle Aged, pubmed-meshheading:20552631-Mutation, pubmed-meshheading:20552631-Prognosis, pubmed-meshheading:20552631-Protein-Serine-Threonine Kinases, pubmed-meshheading:20552631-Survival Rate, pubmed-meshheading:20552631-Tumor Markers, Biological, pubmed-meshheading:20552631-Tumor Suppressor Protein p53, pubmed-meshheading:20552631-Tumor Suppressor Proteins
pubmed:year
2010
pubmed:articleTitle
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
pubmed:affiliation
MLL Munich Leukemia Laboratory, Munich, Germany. claudia.haferlach@mll-online.com
pubmed:publicationType
Journal Article